BioAge Labs (BIOA) said Tuesday its experimental BGE-102 drug demonstrated "best-in-class reductions" in inflammatory biomarkers during a phase 1 trial involving participants with obesity.

Both the 60 mg and 120 mg daily doses lowered high-sensitivity C-reactive protein levels by at least 85% while maintaining a favorable safety profile, the company said.

The company plans to begin a phase 2 study focused on cardiovascular risk during H1, with initial data expected by the end of the year.

BioAge also intends to launch a separate proof-of-concept trial for diabetic macular edema in mid-2026 to evaluate the treatment's effect on retinal diseases.

Shares of the company rose 9% in Tuesday's premarket activity.

Price: 20.49, Change: +1.69, Percent Change: +8.99